Home › Compare › TVAGF vs ABBV
TVAGF yields 235.29% · ABBV yields 3.06%● Live data
📍 TVAGF pulled ahead of the other in Year 1
Combined, TVAGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TVAGF + ABBV for your $10,000?
TVA Group Inc. operates a communications company in Canada. It operates through four segments: Broadcasting, Magazines, Film Production & Audiovisual Services, and Production & Distribution. The company's Broadcasting segment creates, produces, and broadcasts entertainment, sports, news, and public affairs programming, as well as engages in commercial production; operates a French-language television network; markets digital products associated with various televisual brands; and provides custom publishing and specialty services. Its Magazines segment publishes magazines in various fields, such as the arts, entertainment, television, fashion, and decoration; and markets digital products associated with various magazine brands. The company's Film Production & Audiovisual Services segment offers soundstage, mobile, and equipment rental services, as well as dubbing and described video, postproduction and visual effects. Its Production & Distribution segment produces and distributes television shows, movies, and television series worldwide. The company was formerly known as Télé-Métropole Inc. and changed its name to TVA Group Inc. in February 1998. TVA Group Inc. was incorporated in 1960 and is headquartered in Montreal, Canada. TVA Group Inc. is a subsidiary of Quebecor Media Inc.
Full TVAGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.